Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors

BACKGROUND: Monoclonal antibodies targeting programmed death ligand 1 (PD-L1) signaling currently approved for defective mismatch repair (dMMR)/microsatellite instability high (MSI-H) tumors must be delivered by intravenous infusion. Envafolimab, a humanized single-domain anti-PD-L1 antibody fused t...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Hematol Oncol
Asıl Yazarlar: Li, Jian, Deng, Yanhong, Zhang, Weijie, Zhou, Ai-Ping, Guo, Weijian, Yang, Jianwei, Yuan, Ying, Zhu, Liangjun, Qin, Shukui, Xiang, Silong, Lu, Haolan, Gong, John, Xu, Ting, Liu, David, Shen, Lin
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2021
Konular:
Rapid Communication
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8218452/
https://ncbi.nlm.nih.gov/pubmed/34154614
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-021-01095-1
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller